Keywords: Sanofi-Aventis, Regulus, Licensing, MicroRNA, Fibrosis, Alnylam, Isis

Sanofi-Aventis expands into microRNA sector in up to $750 million deal with Regulus

Article | 23 June 2010

French drug major Sanofi-Aventis has increased its research interest into the microRNA sector, signing a strategic alliance with USA-based Regulus ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Sanofi-Aventis

Regulus Therapeutics

Alnylam Pharmaceuticals

Isis Pharmaceuticals

Go to company listing